Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Prevention of cardiovascular disease in clinical practice: The Joint British Societies' (JBS 2) guidelines

Journal of Human Hypertension volume 20, pages 641–645 (2006)Cite this article

Cardiovascular disease (CVD) represents a significant clinical and economic burden to healthcare, accounting for at least 22% of all global deaths.1 The financial burden is equally immense; the annual cost to the European Union is estimated at €169 billion, 62% of which is directly spent on health-care provision.2

Given this significant health-care burden, there exists an enormous potential for risk factor modification and preventative medicine. Ten years ago, the EUROASPIRE I (European Action on Secondary Prevention by Intervention to Reduce Events) survey of patients with established coronary heart disease (CHD) in nine European countries confirmed the substantial potential for cardiac risk factor modification.3 A great deal of investment has taken place in many countries to improve health-care provision and in particular to target patients at high risk of CVD.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bakhai A . The burden of coronary, cerebro vascular and peripheral arterial disease. Pharmacoeconomics 2004; 22 (Suppl 4): 11–18.

    Article  Google Scholar 

  2. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M . Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006 (E-pub ahead of print), available online - www.eurheartj.oxfordjournals.org.

  3. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357 (9261): 972–973.

  4. Zyczkowska J, Klich-Raczka A, Mossakowska M, Gasowski J, Wieczorowska-Tobisb K, Grodzicki T . Blood pressure in centenarians in Poland. J Hum Hypertens 2004; 18 (10): 713–716.

    Article  CAS  Google Scholar 

  5. Zdrojewski T, Szpakowski P, Bandosz P, Pajak A, Wiecek A, Krupa-Wojciechowska B et al. Arterial hypertension in Poland in 2002. J Hum Hypertens 2004; 18 (8): 557–562.

    Article  CAS  Google Scholar 

  6. Kamadjeu RM, Edwards R, Atanga JS, Unwin N, Kiawi EC, Mbanya JC . Prevalence, awareness and management of hypertension in Cameroon: findings of the 2003 Cameroon Burden of Diabetes Baseline Survey. J Hum Hypertens 2006; 20 (1): 91–92.

    Article  CAS  Google Scholar 

  7. Agyemang C, Bruijnzeels MA, Owusu-Dabo E . Factors associated with hypertension awareness, treatment, and control in Ghana, West Africa. J Hum Hypertens 2006; 20 (1): 67–71.

    Article  CAS  Google Scholar 

  8. JBS 2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91: 1–52.

  9. JBS 1. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 1998; 80 (Suppl 2): S1–S29.

  10. Downs GR, Clearfield M, Weiss S, Whitney E, Shapiro DR, Beere PA et al., for the Afcaps/TexCaPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TEXCAPS (Air force/Texas Coronary Atherosclerosis Prevention study). JAMA 1998; 279: 1615–1622.

    Article  CAS  Google Scholar 

  11. Smith SC, Jackson R, Pearson AT, Fuster V, Yusuf S, Faergeman O et al. Principles for national and regional guidelines on cardiovascular disease prevention. A scientific statement from the World Heart and Stroke Forum. Circulation 2004; 109: 3112–3121.

    Article  Google Scholar 

  12. Anderson KM, Odell PM, Wilson PW, Kannel WB . Cardiovascular disease risk profiles. Am Heart J 1990; 121: 293–298.

    Article  Google Scholar 

  13. Green R, Kwok S, Durrington PN . Preventing cardiovascular diseases in hypertension: effects of lowering blood pressure and cholesterol. Q J Med 2002; 95: 821–826.

    Article  CAS  Google Scholar 

  14. Gulliford MC, Charlton J, Latinovic R . Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion? J Hum Hypertens 2005; 19 (2): 111–117.

    Article  CAS  Google Scholar 

  15. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN et al., GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004; 18 (11): 781–788.

    Article  CAS  Google Scholar 

  16. Forouhi NG, Sattar N . CVD risk factors and ethnicity – a homogeneous relationship? Atheroscler Suppl 2006 (E-pub ahead of print).

  17. Gupta M, Brister S . Is South Asian ethnicity an independent cardiovascular risk factor? Can J Cardiol 2006; 22 (3): 193–197.

    Article  CAS  Google Scholar 

  18. Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM . Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ 2002; 325: 1271–1274.

    Article  Google Scholar 

  19. Bhopal R, Fischbacher C, Vartianen E, Unwin N, White M, Alberti G . Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. J Public Health (Oxford) 2005; 27 (1): 93–100.

    Article  Google Scholar 

  20. Quirke T, Gill P, Mant J, Allan T . The applicability of the Framingham coronary heart disease prediction function to black and minority ethnic groups in the UK. Heart 2003; 89: 785–786.

    Article  CAS  Google Scholar 

  21. Aarabi M, Jackson PR . Predicting coronary risk in UK South Asians: an adjustment method for Framingham-based tools. Eur J Cardiovasc Prev Rehabil 2005; 12 (1): 46–51.

    Article  Google Scholar 

  22. Brindle P, May M, Gill P, Cappuccio F Snr, Fischbacher C, Ebrahim S . ETHRISK – A modified Framingham CHD and CVD risk calculator for British black and minority ethnic groups. http://www.epi.bris.ac.uk/cvdethrisk/.

  23. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al, INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366 (9497): 1640–1649.

    Article  Google Scholar 

  24. WHO. World Health Report 2002; Reducing Risk, Promoting Healthy Life. World Health Organization: Geneva, 2002.

  25. Masley SC, Phillips SE, Schocken DD . Blood pressure as a predictor of cardiovascular events in the elderly: the William Hale Research Program. J Hum Hypertens 2006; 20 (6): 392–397.

    Article  CAS  Google Scholar 

  26. Alli C, Mariotti G, Avanzini F, Colombo F, Barlera S, Tognoni G, Studio sulla Pressione Arteriosa nell'Anziano(SPAA). Long-term prognostic impact of repeated measurements over 1 year of pulse pressure and systolic blood pressure in the elderly. J Hum Hypertens 2005; 19 (5): 355–363.

    Article  CAS  Google Scholar 

  27. Wingfield D, Grodzicki T, Palmer AJ, Wells F, Bulpitt CJ, General Practice Hypertension Study Group. Transiently elevated diastolic blood pressure is associated with a gender-dependent effect on cardiovascular risk. J Hum Hypertens 2005; 19 (5): 347–354.

    Article  CAS  Google Scholar 

  28. He FJ, MacGregor GA . Cost of poor blood pressure control in the UK: 62,000 unnecessary deaths per year. J Hum Hypertens 2003; 17 (7): 455–457.

    Article  CAS  Google Scholar 

  29. Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003; 17: 81–86.

    Article  CAS  Google Scholar 

  30. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al., British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18 (3): 139–185.

    Article  CAS  Google Scholar 

  31. Beevers DG . The end of β blockers for uncomplicated hypertension? Lancet 2005; 366: 1510–1512.

    Article  Google Scholar 

  32. Law MR, Wald NJ, Thompson SG . By how much and how quickly does reduction in serum cholesterol concentration lower risk of ishaemic heart disease? BMJ 1994; 308: 367–372.

    Article  CAS  Google Scholar 

  33. LaRosa JC, He J, Vupputuri S . Effect of statins on risk of coronary disease: a meta-analysis of randomised controlled trails. JAMA 1999; 282: 2340–2346.

    Article  CAS  Google Scholar 

  34. Tonelli M, Sacks F, Pfeffer M, Lopez-Jimenez F, Jhangri GS, Curhan G . Effect of pravastatin on blood pressure in people with cardiovascular disease. J Hum Hypertens (E-pub ahead of print: 20 April 2006; doi:10.1038/sj.jhh.1002036).

    Article  CAS  Google Scholar 

  35. Milionis HJ, Liberopoulos EN, Achimastos A, Elisaf MS, Mikhailidis DP . Statins: another class of antihypertensive agents? J Hum Hypertens 2006; 20 (5): 320–335.

    Article  CAS  Google Scholar 

  36. Hoskins MH, Jacobson TA . Missed opportunity in the treatment of hyperlipidemia in patients with coronary heart disease: the primary care setting. J Natl Med Assoc 2006; 98 (1): 58–62.

    PubMed  PubMed Central  Google Scholar 

  37. Almdal T, Scharling H, Jensen JS, Vestergaard H . The independent effect of type 2 diabetes mellitus on ischaemic heart disease, stroke, and death: a population based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164 (13): 1422–1426.

    Article  Google Scholar 

  38. Varughese GI, Patel JV, Lip GY . Blood pressure control in the setting of diabetes mellitus: new targets, new hope for improvement? J Hum Hypertens 2006 (E-pub ahead of print: 13 April 2006; doi:10.1038/sj.jhh.1002029).

    Article  CAS  Google Scholar 

  39. Czupryniak L, Saryusz-Wolska M, Pawlowski M, Loba J . Elevated systolic blood pressure is present in almost all individuals with newly diagnosed diabetes. J Hum Hypertens 2006; 20 (3): 231–233.

    Article  CAS  Google Scholar 

  40. Jafar TH . Blood pressure, diabetes, and increased dietary salt associated with stroke – results from a community-based study in Pakistan. J Hum Hypertens 2006; 20 (1): 83–85.

    Article  CAS  Google Scholar 

  41. Varughese GI, Lip GY . Antihypertensive therapy in diabetes mellitus: insights from ALLHAT and the Blood Pressure-Lowering Treatment Trialists' Collaboration meta-analysis. J Hum Hypertens 2005; 19 (11): 851–853.

    Article  CAS  Google Scholar 

  42. Howard BV, Best LG, Galloway JM, Howard WJ, Jones K, Lee ET et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 2006; 29: 391–397.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Department of Medicine, City Hospital, Birmingham, UK

    S Jessani, T Watson & G Y H Lip

  2. Clinical Sciences Research Institute, Warwick Medical School, Coventry, UK

    F P Cappuccio

Authors
  1. S Jessani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F P Cappuccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Y H Lip
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Y H Lip.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jessani, S., Watson, T., Cappuccio, F. et al. Prevention of cardiovascular disease in clinical practice: The Joint British Societies' (JBS 2) guidelines. J Hum Hypertens 20, 641–645 (2006). https://doi.org/10.1038/sj.jhh.1002058

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1002058

This article is cited by

Search

Advanced search

Quick links